Flow cytometry analysis for the expression of CCR7 and CD45RA on CD8+ T cells directed to gp100209–217, Melan-A/Mart-126–35 and Influenza-Matrix58–66 epitopes in PBL, TILN, and TFLN of melanoma patients
| Tissue | n | aCCR7/CD45RA phenotype of gated CD8+ tetramer+ T cells directed to | bFrequency of tetramer T cells directed to | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| gp100209–217 | Melan-A/Mart-126–35 | Flu-Matrix58–66 | gp100209–217 | Melan-A/Mart-126–35 | Flu-Matrix58–66 | |||||||||||
| +/+ | +/− | −/− | −/+ | +/+ | +/− | −/− | −/+ | +/+ | +/− | −/− | −/+ | |||||
| PBL | 11 | 21 (5–43) | 13 (2–27) | 25 (13–35) | 40 (17–58) | 37 (19–54) | 15 (4–36) | 18 (6–30) | 30 (12–59) | 26 (10–44) | 12 (4–34) | 25 (10–36) | 38 (21–50) | 0.347 (0.038–1.132) | 0.194 (0.058–0.464) | 0.203 (0.044–0.906) |
| cTILN | 7 | 6 (1–11) | 19 (7–42) | 71 (50–83) | 4 (1–8) | 2 (0–5) | 9 (2–17) | 87 (76–98) | 1 (0–3) | 8 (3–20) | 7 (1–12) | 72 (40–86) | 14 (6–30) | 0.499 (0.082–2.332) | 7.063 (1.502–23.285) | 0.179 (0.021–0.528) |
| cTILN | 16 | 65 (26–93) | 18 (7–51) | 8 (0–28) | 9 (0–35) | 69 (28–96) | 16 (4–33) | 9 (0–44) | 6 (0–37) | 70 (37–97) | 19 (3–40) | 6 (0–20) | 5 (0–25) | 0.144 (0.012–0.667) | 0.250 (0.043–0.810) | 0.109 (0.023–0.289) |
| TFLN | 8 | 28 (13–45) | 27 (4–47) | 22 (4–38) | 23 (4–45) | 51 (32–66) | 23 (14–34) | 15 (0–35) | 12 (0–17) | 31 (13–45) | 26 (3–47) | 21 (9–35) | 22 (2–45) | 0.260 (0.073–0.606) | 0.362 (0.123–0.892) | 0.443 (0.086–1.280) |
a Percentage of positive cells (mean value, with range in brackets) for each of the four possible CCR7/CD45RA phenotypes is reported. nd, not done.
b Frequency of tetramer+ T cells (mean value, with range in brackets) is expressed as % of positive cells/CD8+ lymphocytes.
c The two groups of TILN (7 patients versus 16 patients) identified by high versus low frequency to Melan-A/Mart-1 epitope differ for the proportion of tetramer+ T cells expressing a CCR7+/CD45RA+ and a CCR7− CD45RA− phenotype (P < 0.001).